Saturday 17 October 2026
Export ANNX’s income statement to Excel — free account
Annexon, Inc.
ANNX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 17.7% and free cash flow fell 26.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.41
0.19
−5.28%
Follow ANNX
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
5.68 | 10.37 | 14.72 | 11.10 | 11.39 | 33.33 | 9.21 | 13.74 | 1.68 |
Net Debt/EBITDA |
1.11 | 2.05 | 1.83 | 1.69 | 1.89 | 5.59 | 1.37 | 2.37 | (2.28) |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (1.06) |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.89 | 0.85 | 0.90 | 0.82 | 0.81 | 0.75 | 0.74 | 0.93 | 1.02 |
Capex/Depreciation |
(0.06) | (0.01) | (0.09) | (3.10) | (0.77) | (0.70) | (0.54) | (0.03) | 0.00 |
| (82.63%) | (50.84%) | (55.73%) | (61.30%) | (45.24%) | (57.69%) | 46.49% | 33.47% | 34.04% | |
| (66.45%) | (42.67%) | (46.07%) | (49.62%) | (40.54%) | (34.66%) | (78.08%) | (76.76%) | (67.16%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(99.22%) | (46.28%) | (51.49%) | (58.52%) | (53.46%) | (20.37%) | (89.83%) | (41.32%) | (392.13%) |
Average Days of Receivables |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Free Cash Flow per Share |
(1.20) | (0.86) | (1.60) | (2.25) | (2.81) | (3.16) | (66.03) | (42.73) | (0.50) |
Cash per Share |
1.54 | 2.27 | 3.43 | 4.44 | 6.33 | 20.71 | 101.34 | 109.70 | 0.08 |
Shareholders Equity per Share |
1.36 | 2.13 | 3.31 | 4.23 | 6.05 | 20.30 | (231.73) | (159.43) | (1.21) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.36 | 2.13 | 3.31 | 4.23 | 6.05 | 20.30 | (231.73) | (159.43) | (1.21) |
Free Cash Flow |
(186.49) | (118.02) | (121.33) | (122.83) | (107.76) | (53.55) | (28.62) | (17.21) | (19.26) |
Working Capital |
199.56 | 285.95 | 245.93 | 225.74 | 225.95 | 343.39 | 40.48 | 42.38 | 1.98 |
Capital Expenditures |
(0.14) | (0.01) | (0.19) | (6.53) | (1.65) | (0.46) | (0.27) | (0.02) | (0.57) |
Net Current Asset Value |
176.27 | 259.50 | 216.74 | 194.20 | 192.56 | 342.34 | (104.95) | (66.64) | (49.14) |
| Other line items | |||||||||
Quick Ratio |
5.59 | 10.23 | 14.49 | 10.85 | 11.16 | 33.06 | 8.91 | 13.28 | 1.22 |
Depreciation/Fixed assets |
0.20 | 0.17 | 0.15 | 0.13 | 0.12 | 0.34 | 0.23 | 0.21 | 0.10 |
Cash ROIC |
(41.44%) | (19.50%) | (23.78%) | (25.92%) | (22.71%) | (7.70%) | 50.64% | 85.92% | (336.36%) |
Accounts Receivable Turnover |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.19 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2,052.62 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(1.20) | (0.86) | (1.60) | (2.13) | (2.77) | (3.13) | (65.42) | (42.69) | (0.50) |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.12) | (0.04) | (0.03) | (0.62) | (0.04) | 0.00 |
Average Receivables |
— | — | — | — | — | 0.04 | 0.15 | 0.40 | 0.40 |
Average Payables |
12.68 | 7.96 | 6.45 | 9.28 | 7.44 | 3.05 | 1.82 | 1.40 | 1.40 |
Average Assets |
313.82 | 323.87 | 291.39 | 286.07 | 321.49 | 202.92 | 49.02 | 24.07 | 27.99 |
Average Common Equity |
252.38 | 271.83 | 240.88 | 231.55 | 288.09 | 121.91 | (82.33) | (55.21) | (55.21) |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Columns are period end dates